Citations

Showing 10 of 108094 citations.

Bone marrow oxalosis with pancytopenia in a patient with short bowel syndrome: Report of a case and review of the literature
Bering, Jamie , Wiedmeier, Julia E. , Sproat, Lisa , DiBaise, John K. , Bering, Jamie L , Wiedmeier-Nutor, Julia E

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | October 1, 2022 | Volume: 47 | Issue: 1 | Pages: 165-170

10.1002/jpen.2453 | PMID 36181457 Get It

AbstractSystemic oxalosis is a condition in which calcium oxalate crystals deposit into various bodily tissues. Although this may occur as the result of a rare primary syndrome in which an error of glyoxylate metabolism causes an overproduction of oxalate, it is more often seen as a secondary process characterized by increased enteric oxalate absorption. Here, we describe a patient with short bowel syndrome on long‐term parenteral nutrition support who developed a unique manifestation of systemic oxalosis, leading to deposition of oxalate crystals within the bone marrow contributing to pancytopenia. In this report, in addition to reviewing the literature on this presumably rare manifestation of oxalosis, we also discuss its pathogenesis in the setting of short bowel syndrome and its management, including prevention.
Rapid Early Progression (REP) of Glioblastoma Is an Independent Negative Prognostic Factor: Results From a Systematic Review and Meta-Analysis
Hamer, Philip Witt De, Quiñones‐Hinojosa, Alfredo , Waqar, Mueez , Roncaroli, Federico , Lehrer, Eric J. , Palmer, Joshua D. , Villanueva-Meyer, Javier E. , Braunstein, Steve , Hall, Emma , Aznar, Marianne Camille , D’Urso, Pietro Ivo , Trifiletti, Daniel M. , Wesseling, Pieter , Borst, Gerben R.

Mayo Clinic

Neuro-Oncology | October 1, 2022 | Volume: 24 | Issue: Supplement_4 | Pages: iv14-iv14

10.1093/neuonc/noac200.062 Get It

Abstract AIMS In patients with newly-diagnosed glioblastoma, rapid early progression (REP) refers to tumour regrowth between surgery and postoperative chemoradiotherapy. This systematic review and meta-analysis aimed to appraise published data on REP to better characterise and understand this phenomenon. METHOD Systematic searches of MEDLINE, EMBASE and the Cochrane database from inception to 21/10/21. Studies describing the incidence of REP – tumour growth between the postoperative MRI scan and pre-radiotherapy MRI scan in newly-diagnosed glioblastoma, were included. The primary outcome was REP incidence. RESULTS From 1590 search results, 9 studies were included with 716 patients. The median age was 56.9 years (IQR 54.0- 58.8 years). There was a male predominance with a median male-to-female ratio of 1.4 (IQR 1.1-1.5). The median number of days between MRI scans was 34 days (IQR 18-45 days). The mean incidence rate of REP was 45.9% (range 19.3%-72.0%) and significantly lower in studies employing functional imaging to define REP (p<0.001). REP/non-REP groups were comparable with respect to age (p=0.99), gender (p=0.33) and time between scans (p=0.81). REP was associated with shortened overall survival (HR 1.78, 95% CI 1.30-2.43, p<0.001), shortened progression-free survival (HR 1.78, 95% CI 1.30-2.43, p<0.001), subtotal resection (OR 6.96, 95% CI 4-51-10.73, p<0.001) and IDH wildtype versus mutant tumours (OR 0.20, 95% CI 0.02-0.38, p=0.03). MGMT promoter methylation was not associated with REP (OR 1.29, 95% CI 0.72-2.28, p=0.39). CONCLUSION REP occurs in almost half of patients with newly-diagnosed glioblastoma and has a strongly negative prognostic effect. Future studies should investigate its biology and effective treatment strategies.
Glioma Espionage From Longitudinal CSF Proteomics
Riviere-Cazaux, Cécile , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | October 1, 2022 | Volume: 24 | Issue: Supplement_4 | Pages: iv11-iv12

10.1093/neuonc/noac200.052 Get It

Abstract AIMS Rapid, detailed feedback is needed to understand the individualized biological impacts of novel glioma therapies. We are performing glioma biomarker discovery by serial cerebrospinal fluid (CSF) sampling from Ommaya reservoirs to determine how the CSF proteome can reveal early longitudinal intelligence regarding glioma status, biology, and therapeutic response. METHOD Global proteomic analysis of CSF was performed on the Somalogic platform – an aptamer-based technology for highly sensitive and specific analysis of over 7,000 proteins. Discovery analysis comprised of the top-500 ranked proteins in CSF from seven patients with high-grade gliomas (HGG) versus non-glioma controls. The top-500 HGG proteins were then preliminarily filtered to include only proteins that met two additional criteria of decrease with resection and increase with recurrence in individual paired patient samples. RESULTS Proteomic enrichment analysis revealed a conserved HGG CSF proteomic signature defined by 79 proteins, including ones known to be over-expressed in solid tumor malignancies, such as retinoblastoma binding protein 4, heat shock protein 90, and sorcin. The HGG proteomic signature was consistently enriched in an independent validation cohort consisting of 13 gliomas diverse in primary versus recurrent status, subtype, and grade, when compared to control CSF samples. Encouragingly, proteins in the HGG signature decreased in the two patients for whom CSF was collected prior to and after resection (both at POD16 and POD18) with decreased tumor burden. CONCLUSION Our data demonstrate the ability to gain detailed, individualized insights regarding glioma biology, tumor burden, and evolution through global CSF proteomics acquired from longitudinal access to gliomas via Ommaya reservoirs.
A new look at cognitive functioning in pediatric MS
Krupp, Lauren , Waltz, Michael , Casper, T. Charles , Belman, Anita , Wheeler, Yolanda , Ness, Jayne , Gorman, Mark , Mar, Soe , Schreiner, Teri , Tillema, Jan‐Mendelt , Lotze, Timothy , Aaen, Greg, Rose, John , Chitinis, Tanuja, George, Allan , Krupp, Lauren , Weinstock‐Guttman, Bianca , Rensel, Mary R. , Chitnis, Tanuja , Charvet, Leigh E , Waubant, Emmanuelle L. , Graves, Jennifer , Benson, Leslie, Goyal, Manu S. , Schreiner, Teri , Rodriguez, Moses , Aaen, Gregory , Charvet, Leigh

Mayo Clinic

Multiple Sclerosis Journal | October 1, 2022 | Volume: 29 | Issue: 1 | Pages: 140-149

10.1177/13524585221123978 | PMID 36189711 Get It

Objective: Cognitive involvement in pediatric multiple sclerosis (MS) relative to adult MS is less defined. This study advances our understanding by measuring cognitive performances in pediatric MS, adult MS, and pediatric healthy controls. Methods: Consecutive relapsing pediatric MS participants from the United States Network of Pediatric MS Centers were compared with pediatric healthy controls and adults with relapsing MS. Participants were compared on two screening batteries: the Brief International Cognitive Assessment for MS and the Cogstate Brief Battery. Results were transformed to age-normative z scores. Results: The pediatric groups (MS vs. Healthy Controls) did not differ on either battery’s composite mean score or individual test scores ( ps > 0.32), nor in the proportions impaired on either battery, Brief International Cognitive Assessment for MS (26% vs. 24%, p = 0.83); Cogstate Brief Battery (26% vs. 32%, p = 0.41). The pediatric versus adult MS group even after controlling for differences in disease duration performed better on the Brief International Cognition Assessment for MS composite ( p = 0.03), Symbol Digit Modalities Test ( p = 0.02), Rey Auditory Verbal Learning Test ( p = 0.01), and Cogstate choice reaction time ( p < 0.001). Conclusion: Pediatric MS patients do not differ from healthy pediatric controls on cognitive screens but perform better than adults with MS.
Guidelines for Sexual Health Care for Prostate Cancer Patients: Recommendations of an International Panel
Wittmann, Daniela , McCaughan, Eilís , Faraday, Martha M., Duby, Ashley , Matthew, Andrew, Incrocci, Luca , Nelson, Christian J. , Elliott, Stacy , McLeod, Deborah , Yap, Tet , Higano, Celestia S. , Capellari, Emily, Glodé, Michael, Howell, Doug, Bennett, Nelson , Trost, Landon , Ouma, P Odiyo, Wang, Run , Salter, Carolyn A. , Skolarus, Ted A. , McPhail, John, McPhail, S. Morton, Brandon, Jan, Northouse, Laurel , Paich, Kellie , Pollack, Craig Evan , Shifferd, Jen, Erickson, Kim, Mulhall, John P. , Nelson, Christian J , Mehta, Akanksha , Burnett, Arthur L. “Bud” , Koontz, Bridget F. , Bober, Sharon L. , Capogrosso, Paolo , Loeb, Stacy , Goltz, Heather Honoré , Kirby, Michael G. , McPhail, Susan, Shifferd, Jennifer

Mayo Clinic

The Journal of Sexual Medicine | October 1, 2022 | Volume: 19 | Issue: 11 | Pages: 1655-1669

10.1016/j.jsxm.2022.08.197 | PMID 36192299 Get It

AbstractBackgroundPatients with prostate cancer suffer significant sexual dysfunction after treatment which negatively affects them and their partners psychologically, and strain their relationships.AimWe convened an international panel with the aim of developing guidelines that will inform clinicians, patients and partners about the impact of prostate cancer therapies (PCT) on patients’ and partners’ sexual health, their relationships, and about biopsychosocial rehabilitation in prostate cancer (PC) survivorship.MethodsThe guidelines panel included international expert researchers and clinicians, and a guideline methodologist. A systematic review of the literature, using the Ovid MEDLINE, Scopus, CINAHL, PsychINFO, LGBT Life, and Embase databases was conducted (1995–2022) according to the Cochrane Handbook for Systematic Reviews of Interventions. Study selection was based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Each statement was assigned an evidence strength (A-C) and a recommendation level (strong, moderate, conditional) based on benefit/risk assessment, according to the nomenclature of the American Urological Association (AUA). Data synthesis included meta-analyses of studies deemed of sufficient quality (3), using A Measurement Tool to Assess Systematic Reviews (AMSTAR).OutcomesGuidelines for sexual health care for patients with prostate cancer were developed, based on available evidence and the expertise of the international panel.ResultsThe guidelines account for patients’ cultural, ethnic, and racial diversity. They attend to the unique needs of individuals with diverse sexual orientations and gender identities. The guidelines are based on literature review, a theoretical model of sexual recovery after PCT, and 6 principles that promote clinician-initiated discussion of realistic expectations of sexual outcomes and mitigation of sexual side-effects through biopsychosocial rehabilitation. Forty-seven statements address the psychosexual, relationship, and functional domains in addition to statements on lifestyle modification, assessment, provider education, and systemic challenges to providing sexual health care in PC survivorship.Clinical ImplicationsThe guidelines provide clinicians with a comprehensive approach to sexual health care for patients with prostate cancer.Strengths & LimitationsThe strength of the study is the comprehensive evaluation of existing evidence on sexual dysfunction and rehabilitation in prostate cancer that can, along with available expert knowledge, best undergird clinical practice. Limitation is the variation in the evidence supporting interventions and the lack of research on issues facing patients with prostate cancer in low and middle-income countries.ConclusionThe guidelines document the distressing sexual sequelae of PCT, provide evidence-based recommendations for sexual rehabilitation and outline areas for future research.
The other COVID ‐19 survivors: Timing, duration, and health impact of post‐acute sequelae of SARS‐CoV ‐2 infection
Lambert, Natalie , Corps, Survivor, El‐Azab, Sarah A. , Ramrakhiani, Nathan S. , Barisano, Anthony , Lu, Yu , Taylor, Kaitlyn, Esperança, Álvaro , Mendiola, Christian , Abrahim, Heather L. , Hughes, Thomas , Rahmani, Amir M. , Chakraborty, Rana , Corps, Survivor, Yu, Lu, Downs, Charles A , Borelli, Jessica L. , Pinto, Melissa D.

Mayo Clinic

Journal of Clinical Nursing | October 1, 2022 | Volume: 33 | Issue: 1 | Pages: 76-88

10.1111/jocn.16541 | PMID 36181315 Get It

Abstract Aims and Objectives To determine the frequency, timing, and duration of post‐acute sequelae of SARS‐CoV‐2 infection (PASC) and their impact on health and function. Background Post‐acute sequelae of SARS‐CoV‐2 infection is an emerging major public health problem that is poorly understood and has no current treatment or cure. PASC is a new syndrome that has yet to be fully clinically characterised. Design Descriptive cross‐sectional survey ( n = 5163) was conducted from online COVID‐19 survivor support groups who reported symptoms for more than 21 days following SARS‐CoV‐2 infection. Methods Participants reported background demographics and the date and method of their covid diagnosis, as well as all symptoms experienced since onset of covid in terms of the symptom start date, duration, and Likert scales measuring three symptom‐specific health impacts: pain and discomfort, work impairment, and social impairment. Descriptive statistics and measures of central tendencies were computed for participant demographics and symptom data. Results Participants reported experiencing a mean of 21 symptoms (range 1–93); fatigue (79.0%), headache (55.3%), shortness of breath (55.3%) and difficulty concentrating (53.6%) were the most common. Symptoms often remitted and relapsed for extended periods of time (duration M = 112 days), longest lasting symptoms included the inability to exercise ( M = 106.5 days), fatigue ( M = 101.7 days) and difficulty concentrating, associated with memory impairment ( M = 101.1 days). Participants reported extreme pressure at the base of the head, syncope, sharp or sudden chest pain, and “brain pressure” among the most distressing and impacting daily life. Conclusions Post‐acute sequelae of SARS‐CoV‐2 infection can be characterised by a wide range of symptoms, many of which cause moderate‐to‐severe distress and can hinder survivors' overall well‐being. Relevance to Clinical Practice This study advances our understanding of the symptoms of PASC and their health impacts.
A Simple Method to Improve Intraoperative Localization of Fiducial Markers during Lung Resections
He, Shengliang, Beamer, Staci E. , Jaroszewski, Dawn E. , D’Cunha, Jonathan, Ravanbakhsh, Samine, Beamer, Staci, Jaroszewski, Dawn, Ravanbakhsh, Samine

Mayo Clinic

The Thoracic and Cardiovascular Surgeon Reports | September 30, 2022 | Volume: 11 | Issue: 01 | Pages: e58-e60

10.1055/s-0042-1756299 | PMID 36187730 Get It

Abstract Background Lung cancer screening programs have increased the detection of early-stage lung cancer. High-resolution computed tomography can detect small, low-density pulmonary nodules, or ground-glass opacities. Obtaining a tissue diagnosis can be challenging, often necessitating surgical diagnosis. Preoperative localization and intraoperative fluoroscopy are valuable tools to guide resections for small pulmonary nodules. Case Description We present three cases using intraoperative fluoroscopy and Faxitron Bioptics that enhanced our certainty of resection of nonpalpable nodules. Conclusion We support the use of intraoperative fluoroscopy with the unique addition of Faxitron BioVision as safe and reliable methods to enhance the certainty of resection.
Characterization of Immune Exhaustion and Suppression in the Tumor Microenvironment of Splenic Marginal Zone Lymphoma
Jalali, Shahrzad , Tang, Xinyi , Yu, Yue , Pritchett, Joshua C. , Price-Troska, Tammy, Novak, Anne J. , Ansell, Stephen M. , Pritchett, Joshua , Anagnostou, Theodora , Yang, Zhi-Zhang , Kim, Hyo Jin , Villasboas, José C. , Mondello, Patrizia

Mayo Clinic

No container title available | September 30, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2106183/v1 Get It

Abstract The role and immunological constitution of the tumor microenvironment (TME) in splenic marginal zone lymphoma (sMZL) is largely unknown and studies on the phenotype and subset composition of intratumoral T cells are lacking. In the present study, we evaluated 36 sMZL spleen specimens by single cell analysis to gain a better understanding of the TME in sMZL. Using mass cytometry (CyTOF), we observed that the TME in sMZL is distinct from that of control non-malignant reactive spleen (rSP). We found that the number of TFH cells varied greatly in sMZL, ICOS+ TFH cells were more abundant in sMZL than rSP, and TFH cells positively correlated with increased numbers of memory B cells. Treg cell analysis revealed that TIGIT+ Treg cells are enriched in sMZL and correlate with suppression of TH17 and TH22 cells. Intratumoral CD8+ T cells were comprised of subsets of short-lived, exhausted and late-stage differentiated cells, thereby functionally impaired. We observed that T-cell exhaustion was present in sMZL and TIM-3 expression on PD-1low cells identified cells with severe immune dysfunction. Gene expression profiling by CITE-seq analysis validated this finding. Taken together, our data sugget that the TME as a whole, and T-cell population specifically, are heterogenous in sMZL and immune exhaustion is one of the major factors impairing T-cell function.
Novel Application of 7T MRI in CSF1R -Related Leukoencephalopathy
Dulski, Jarosław , Middlebrooks, Erik H. , Wszołek, Zbigniew K. , Wszolek, Z.K. , Middlebrooks, Erik H , Dulski, Jaroslaw

Mayo Clinic

Neurology | September 30, 2022 | Volume: 99 | Issue: 24 | Pages: 1110-1111

10.1212/wnl.0000000000201450 | PMID 36180242 Get It